A new molecule to fight type 2 diabetes and non-alcoholic fatty liver disease

ScienceDaily | 4/10/2019 | Staff
KHALEDKHALED (Posted by) Level 3
Other participants in the study, published in the journal British Journal of Pharmacology, are the members of the teams led by the researchers Francesc Villarroya, from the Faculty of Biology and the Institute of Biomedicine of the University of Barcelona (IBUB) and member of the Physiopathology of Obesity and Nutrition Networking Biomedical Research Centre (CIBERobn) and the Research Institute Sant Joan de Déu; and Santiago Vázquez, from the Pharmaceutical Chemistry Unit of the Faculty of Pharmacy and Food Sciences of the UB and IBUB.

The FGF21 hormone -the fibroblast growth factor 21- is an endocrine factor with a determining role in the energetic metabolism as an anti-diabetes and anti-obesity agent. This hormone, which mainly synthetises the liver, is regarded as a potential therapeutic target to treat type 2 diabetes and the non-alcoholic fatty liver disease, which usually occur due obesity and insulin resistance. However, the FGF21 analogue compounds that showed pharmaceutical activity in animal models require subcutaneous injection, and can generate adverse effects (loss of bone mass, increase of heart rate and arterial pressure, etc.).

Study - Levels - FGF21 - Liver - Plasma

According to the new pre-clinical study, levels of FGF21 in the liver and plasma can increase through oral administration of the EPB-53 molecule. "This effect is possible because EPB-53 is a molecule that activates HRI (eIF2? kinase regulated by hemo group), a kinase...
(Excerpt) Read more at: ScienceDaily
Wake Up To Breaking News!
Tyranny has such cute names, like Democrat, Republican, Congress, Senate...
Sign In or Register to comment.

Welcome to Long Room!

Where The World Finds Its News!